Abstract
The speaker will present the Innovative Partnership for Action Against Cancer (iPAAC) Joint Action (JA), which is aiming to develop innovative approaches to advances in cancer control and a Roadmap on Implementation and Sustainability of Cancer Control Actions, identifying areas of relevance to AMR. The issue of AMR is an important issue in view of cancer management. It pertains both to the control of one of the pathogens clearly identified as conducive to cancer - Helicobacter pylori as well as to the issues arising from the vulnerability of the cancer patients in the course of oncological treatment. In the previous JA on Cancer Joint Action on Cancer Control (CanCon), an expert consensus process led to the conclusion that population-based screening for Helicobacter pylori, followed by antibiotic treatment at large scale could trigger AMR, even if it could offset some morbidity due to stomach cancer. It is clear that further research activity is necessary to explore this issue since stomach cancer remains a public health challenge. This is important because of late stage detection, resulting in poor survival. The other important issue is the need to protect cancer patients in treatment and beyond by securing effective antibiotic treatment for infections arising from their condition and/or following their treatment.
Role of Helicobacter pylori in stomach cancer after partial gastrectomy for benign ulcer disease
